Tonix Pharmaceuticals Holding Corp. a company that is developing innovative pharmaceutical products to address public health challenges, announced it will present additional analyses of data from its Phase 2 study in military-related posttraumatic stress disorder, or PTSD, at the 72nd Annual Scientific Convention of the Society of Biological Psychiatry (SOBP) on May 20, 2017 in San Diego.
[adsense:336x280:8701650588]
Gregory Sullivan, M.D., chief medical officer of Tonix, will present moderators and mediators analyses from Tonix’s Phase 2 AtEase study of TNX-102 SL*. TNX-102 SL is the first PTSD drug candidate designated by the U.S. Food and Drug Administration (FDA) as a Breakthrough Therapy.
A moderator is a characteristic of participants going into the study that is associated with a response to treatment, while a mediator is a clinical finding that the response to therapy may depend on, such as sleep quality. Details of the poster presentation follow.
